Immuron Submits Phase 2 Study Report to FDA, Prepares for End-of-Phase 2 Meeting, Takes Next Step Toward Phase 3 Trial

-1.44% Pre

Immuron Limited Sponsored ADR

IMRN

0.00

Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food and Drug Administration (FDA) for the recently completed Phase 2 study and will soon request an end of Phase 2 meeting which is a pre-cursor to proceeding to Phase 3.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs

Discovering US Market Gems October 2025

'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment

A Look at Bicara Therapeutics’s Valuation Following FDA Breakthrough Therapy Designation and Positive ASCO Data

How Investors Are Reacting To Nektar Therapeutics (NKTR) Securing FDA Fast Track For Eczema Drug Candidate

The China National Medical Products Administration Has Approved GSK's Shingrix Vaccine For The Prevention Of Shingles (Herpes Zoster) In Adults Who Are At Increased Risk

Cingulate Announces That U.S. FDA Accepts For Review Its New Drug Application For CTx-1301, Its Lead ADHD Treatment Candidate For Children And Adults

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target